美国食品药品监督管理局批准了布里斯托尔·迈尔斯·斯奎布公司在70多年来首个新的精神分裂症治疗方法Cobenfy. FDA approves first new schizophrenia treatment, Cobenfy, by Bristol Myers Squibb in 70+ years.

美国食品和药物管理局批准了布里斯托尔·迈尔斯·斯奎布公司的新型精神分裂症治疗药物Cobenfy, The FDA has approved Cobenfy, a novel schizophrenia treatment from Bristol Myers Squibb, marking the first new drug type in over 70 years. 预计将于10月下旬推出的两日避孕药,每月费用为1 850美元,或每年保险前费用为22 500美元。 The twice-daily pill, expected to launch in late October, costs $1,850 monthly or $22,500 annually before insurance. Cobenfy的目标是大脑受体减少症状,而不产生典型的抗精神病副作用,为美国近300万受影响成人提供急需的选择。 Cobenfy targets brain receptors to reduce symptoms without typical antipsychotic side effects, providing a much-needed option for the nearly 3 million affected adults in the U.S.